MXPA99010523A - Metodos para mejorar el funcionamiento del tractogastrointestinal superior. - Google Patents

Metodos para mejorar el funcionamiento del tractogastrointestinal superior.

Info

Publication number
MXPA99010523A
MXPA99010523A MXPA99010523A MX9910523A MXPA99010523A MX PA99010523 A MXPA99010523 A MX PA99010523A MX PA99010523 A MXPA99010523 A MX PA99010523A MX 9910523 A MX9910523 A MX 9910523A MX PA99010523 A MXPA99010523 A MX PA99010523A
Authority
MX
Mexico
Prior art keywords
upper gastrointestinal
methods
glp
gastrointestinal tract
tissue
Prior art date
Application number
MXPA99010523A
Other languages
English (en)
Spanish (es)
Inventor
J Drucker Daniel
Original Assignee
Ontario Inc 1149336
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9715481.9A external-priority patent/GB9715481D0/en
Priority claimed from US09/059,504 external-priority patent/US6051557A/en
Application filed by Ontario Inc 1149336 filed Critical Ontario Inc 1149336
Publication of MXPA99010523A publication Critical patent/MXPA99010523A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA99010523A 1997-05-16 1998-05-15 Metodos para mejorar el funcionamiento del tractogastrointestinal superior. MXPA99010523A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4675497P 1997-05-16 1997-05-16
GBGB9715481.9A GB9715481D0 (en) 1997-07-23 1997-07-23 Methods of enhancing functioning of the upper gastrointestinal tract
US09/059,504 US6051557A (en) 1997-05-16 1998-04-13 Methods of enhancing functioning of the upper gastrointestinal tract
PCT/CA1998/000497 WO1998052600A1 (en) 1997-05-16 1998-05-15 Methods of enhancing functioning of the upper gastrointestinal tract

Publications (1)

Publication Number Publication Date
MXPA99010523A true MXPA99010523A (es) 2004-09-01

Family

ID=27268946

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA99010523A MXPA99010523A (es) 1997-05-16 1998-05-15 Metodos para mejorar el funcionamiento del tractogastrointestinal superior.

Country Status (13)

Country Link
EP (1) EP0981362B1 (https=)
JP (2) JP4699576B2 (https=)
CN (1) CN1264307B (https=)
AT (1) ATE253375T1 (https=)
AU (1) AU746633B2 (https=)
BR (1) BR9808804A (https=)
CA (1) CA2289652C (https=)
DE (1) DE69819488T2 (https=)
DK (1) DK0981362T3 (https=)
ES (1) ES2210756T3 (https=)
MX (1) MXPA99010523A (https=)
PT (1) PT981362E (https=)
WO (1) WO1998052600A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2289652C (en) * 1997-05-16 2012-02-28 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
GB9905416D0 (en) * 1999-03-09 1999-05-05 Allelix Biopharma Small molecules having GLP-2 like activity
RU2164349C1 (ru) * 1999-07-27 2001-03-20 Нижегородская государственная медицинская академия Способ определения стоматологического статуса
AU2020501A (en) * 1999-12-08 2001-06-18 1149336 Ontario Inc. Chemotherapy treatment
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
EP1970072A1 (en) * 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
EP1809318B1 (en) 2004-11-01 2013-06-12 NPS Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
UA95235C2 (en) 2005-05-04 2011-07-25 Зииланд Фарма А/С Glucagon-like-peptide-2 (glp-2) analogues
CN101573376B (zh) 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2(glp-2)类似物
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
JP5908478B2 (ja) * 2010-08-30 2016-04-26 エヌピーエス ファーマシューティカルズ インコーポレイテッドNps Pharmaceuticals, Inc. h「Gly2」GLP−2の固相合成
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
CN106167789B (zh) * 2015-05-21 2020-08-04 中国科学院上海营养与健康研究所 低氧处理的间充质干细胞及其应用
EP3551651B1 (en) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
IL299864B2 (en) 2017-06-16 2024-06-01 Zealand Pharma As Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
CN108273038B (zh) * 2018-03-16 2019-03-19 中国人民解放军军事科学院军事医学研究院 防治肠型放射病的药物组合物
CN110226566A (zh) * 2019-07-12 2019-09-13 南京中医药大学 一种放射性口腔黏膜炎动物模型的造模方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27885A (da) * 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP1231219B1 (en) * 1996-04-12 2010-08-25 1149336 Ontario Inc. GLucagon-like peptide-2 analogs
EP1012186B1 (en) * 1996-12-06 2002-07-17 Amgen Inc., Use of a kgf protein product(s) and a glp-2 protein product(s) for the preparation of a medicament
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2289652C (en) * 1997-05-16 2012-02-28 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract

Also Published As

Publication number Publication date
HK1030160A1 (en) 2001-04-27
JP4699576B2 (ja) 2011-06-15
BR9808804A (pt) 2001-09-18
ATE253375T1 (de) 2003-11-15
WO1998052600A1 (en) 1998-11-26
DE69819488D1 (de) 2003-12-11
AU7516398A (en) 1998-12-11
EP0981362B1 (en) 2003-11-05
ES2210756T3 (es) 2004-07-01
CN1264307A (zh) 2000-08-23
CA2289652C (en) 2012-02-28
CN1264307B (zh) 2013-10-30
JP2002502369A (ja) 2002-01-22
DE69819488T2 (de) 2004-08-26
DK0981362T3 (da) 2004-03-15
EP0981362A1 (en) 2000-03-01
PT981362E (pt) 2004-03-31
JP2009280598A (ja) 2009-12-03
WO1998052600A9 (en) 2000-03-09
AU746633B2 (en) 2002-05-02
CA2289652A1 (en) 1998-11-26

Similar Documents

Publication Publication Date Title
MXPA99010523A (es) Metodos para mejorar el funcionamiento del tractogastrointestinal superior.
ATE233096T1 (de) Zusammensetzungen und methoden zur steigerung der darmfunktion
Layer et al. Altered postprandial motility in chronic pancreatitis: role of malabsorption
MXPA05002991A (es) Analogos de ghrh.
Morley The aging gut: physiology
DE69736634D1 (de) Antagonisten des intestinotrophen glp-2 peptides
DK0810829T3 (da) Aminosyresammensætninger og anvendelse deraf til klinisk ernæring
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
ATE259829T1 (de) Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
MXPA04005053A (es) Metodos y composiciones para tratar lesiones del epitelio respiratorio.
EP1792915A3 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
EP0797999A3 (en) Formulations of obesity protein
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
Melvin et al. The gut as an endocrine organ: role in the regulation of food intake and body weight
Pereira et al. New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome
DE60326723D1 (de) Verwendung von zusammensetzungen mit der biologischen aktivität der vasoaktiven intestinalen peptide zur behandlung von sarcoidose
Nustede et al. Plasma concentrations of neurotensin and CCK in patients with chronic pancreatitis with and without enzyme substitution
Myojo et al. Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro
JP2013501736A (ja) 神経変性の修復方法
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
WO2005072277A3 (en) Amidated parathyroid hormone fragments and uses thereof
Betancur et al. Corticosteroid regulation of IL-1 receptors in the mouse hippocampus: effects of glucocorticoid treatment, stress, and adrenalectomy
YAMASHITA et al. Gastrointestinal hormone in dumping syndrome and reflux esophagitis after gastric surgery
Kasperlik-Zaluska et al. ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson's syndrome
AU2003280523A1 (en) Prevention, therapy and prognosis/monitoring in sepsis and septic shock

Legal Events

Date Code Title Description
FG Grant or registration